Results 61 to 70 of about 2,525 (153)

Outsmarting Nightmare: Drug Resistance in Acinetobacter baumannii

Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2025, Issue 1, 2025.
Acinetobacter baumannii is a critical nosocomial pathogen recognized by the WHO as a top‐priority threat due to its extensive drug resistance, particularly in carbapenem‐resistant Acinetobacter baumannii (CRAB) strains. According to recent CDC reports, CRAB is one of the most urgent causes of hospital‐acquired infections, driving longer hospital stays,
Annepu Praveen, Amjuri Sinduja, Mukesh Kumar Yadav, Divakar Sharma, Amit Singh, Satabdi Datta Choudhury   +5 more
wiley   +1 more source

Cefiderocol‐Resistant Elizabethkingia anophelis Bacteremia Following WATCHMAN Implantation: A Case Report and Review of the Literature

Case Reports in Infectious Diseases, Volume 2025, Issue 1, 2025.
Elizabethkingia anophelis is an emerging pathogen associated with nosocomial and community outbreaks. Treatment of infection caused by E. anophelis is not well‐defined given its extensive drug resistance profile, and infection carries a poor prognosis. E.
Anna DeFrank, Michael Bosco, Sigridh Muñoz Gómez, Amit Dhaliwal, Priya Gusain   +4 more
wiley   +1 more source

Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections—In Vitro Susceptibility Testing

Pharmaceuticals
Antimicrobial resistance is a major global health issue. Metallo-β-lactamases (MBL), in particular, are problematic because they can inactivate all classes of β-lactams except aztreonam.
Małgorzata Brauncajs, Filip Bielec, Marlena Malinowska, Dorota Pastuszak-Lewandoska   +3 more
doaj   +1 more source

Activity of imipenem/relebactam against carbapenemase-producing Enterobacteriaceae with high colistin resistance

Journal of Antimicrobial Chemotherapy, 2019
Abstract Objectives Imipenem/relebactam, an investigational β-lactam/β-lactamase inhibitor combination for treatment of Gram-negative infections, and comparators including ceftazidime/avibactam, piperacillin/tazobactam and colistin were tested for activity against representative carbapenemase ...
Jessica Carpenter, Nick Neidig, Alex Campbell, Tanner Thornsberry, Taylor Truex, Tiffany Fortney, Yunliang Zhang, Karen Bush   +7 more
openaire   +2 more sources

Carbapenem‐Resistant Klebsiella pneumoniae Isolated From a Patient in a Midwestern U.S. Hospital With a History of Indian Travel: Therapeutic Strategies and Clinical Outcomes

Case Reports in Infectious Diseases, Volume 2025, Issue 1, 2025.
Carbapenemases have had increasing prevalence within the United States and worldwide. Here, we present a case of carbapenem‐resistant Klebsiella pneumoniae (CRKP) which is unique due to the rarity of multiple mechanisms of resistance within the Klebsiella pneumoniae harboring New Delhi metallo‐β‐lactamases (NDM), oxacillinase‐48 (OXA‐48)‐like, and ...
Christopher Phan, Kristen Tsai, Christian M. Gill, Robin Chamberland, Christian Hendrix, Rong Hou, Dawei Cui   +6 more
wiley   +1 more source

Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence

Life
(1) Background: Infections caused by multidrug-resistant (MDR) bacteria represent one of the major global public health problems of the 21st century. Beta-lactam antibacterial agents are commonly used to treat infections due to Gram-negative pathogens. New β-lactam/β-lactamase inhibitor combinations are urgently needed.
Sansone, Pasquale, Giaccari, Luca Gregorio, Di Flumeri, Giusy, Pace, Maria Caterina, Pota, Vincenzo, Coppolino, Francesco, Brunetti, Simona, Aurilio, Caterina   +7 more
openaire   +4 more sources

Spotlight commentary: Treatment of multidrug‐resistant Gram‐negative infections in the era of growing antimicrobial resistance

British Journal of Clinical Pharmacology, Volume 91, Issue 9, Page 2485-2489, September 2025.
Luka Bielen, Andro Vujević, Luka Csenar
wiley   +1 more source

Revisiting the Metallo‐β‐Lactamase–Mediated Antibiotic Resistance: Exploring Novel Mechanisms and Therapeutic Strategies

International Journal of Microbiology, Volume 2025, Issue 1, 2025.
β‐Lactam resistance is one of the major health concerns today, primarily due to enzymes called β‐lactamases. Metallo‐β‐lactamases (MβLs) can cleave a wide range of β‐lactam antibiotics, including carbapenems. These enzymes require zinc (Zn) ions to function and can be inhibited by conventional β‐lactamase inhibitors.
Jahanvi Saini, Silvi Gautam, Divakar Sharma, Ankit Khanduri, Divya Venugopal, Guilherme Dilarri   +5 more
wiley   +1 more source

A Focused Review on Commercially Available Automated Systems for Antibiotic Susceptibility Testing

Journal of Tropical Medicine, Volume 2025, Issue 1, 2025.
The battle against antibiotic resistance demands innovative solutions for efficient and accurate antibiotic susceptibility testing (AST). Traditional methods, though reliable, are often time‐consuming and labor‐intensive, limiting their ability to provide timely results in clinical settings.
Qumars Ghavami, Haider Abd Ulhai Nasser, Seyedeh Shadi Vaziri, Majid Taati Moghadam, Rajib Chowdhury   +4 more
wiley   +1 more source

Susceptibility to Imipenem/Relebactam of Pseudomonas aeruginosa and Acinetobacter baumannii Isolates from Chinese Intra-Abdominal, Respiratory and Urinary Tract Infections: SMART 2015 to 2018

Infection and Drug Resistance, 2021
Hui Zhang,1,* Peiyao Jia,1,2,* Ying Zhu,1,2,* Ge Zhang,1 Jingjia Zhang,1 Wei Kang,1 Simeng Duan,1 Weijuan Zhang,3 Qiwen Yang,1 Yingchun Xu1 1Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking ...
Zhang H, Jia P, Zhu Y, Zhang G, Zhang J, Kang W, Duan S, Zhang W, Yang Q, Xu Y   +9 more
doaj